We are live on ! Find out more
SXTC icon

China SXT Pharmaceuticals
SXTC

2 hedge funds and large institutions have $436K invested in China SXT Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more capital invested

Capital invested by funds: $264K → $436K (+$172K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$155K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$155K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$13K
2
Bank of America
Bank of America
North Carolina
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$126K +$155K +1 New
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$94K +$155K +1 New
Citadel Advisors
3
Citadel Advisors
Florida
$75K – – –
TSS
4
Two Sigma Securities
New York
$39K – – –
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$31K – – –
VF
6
Virtu Financial
New York
$25K – – –
UBS Group
7
UBS Group
Switzerland
$15K – – –
Citigroup
8
Citigroup
New York
$10K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$7K – – –
CAN
10
Cetera Advisor Networks
California
$6K – – –
Squarepoint
11
Squarepoint
New York
$5K – – –
Millennium Management
12
Millennium Management
New York
$3K – – –
Bank of America
13
Bank of America
North Carolina
– -$3K – –
Two Sigma Advisers
14
Two Sigma Advisers
New York
– -$13K – –

SXTC Hedge Fund Activity: Q1 2022 in Review

2 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q1 2022, worth a combined $436K — up 65% from $264K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SXTC positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $155K. The largest seller was Two Sigma Advisers, cutting an estimated $13K.

  • 2 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q1 2022, up from 0 in Q4 2021.
  • Funds reported $436K of China SXT Pharmaceuticals stock for Q1 2022, up 65% quarter-over-quarter.
  • 2 funds opened new China SXT Pharmaceuticals positions in Q1 2022 and 0 closed out, a net change of +2 holders.
  • The largest China SXT Pharmaceuticals buyer in Q1 2022 was Renaissance Technologies, an estimated $155K added.
  • The largest China SXT Pharmaceuticals seller in Q1 2022 was Two Sigma Advisers, an estimated $13K sold.

Based on aggregated 13F filings for Q1 2022.